Lv5
1310 积分 2024-11-12 加入
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
1个月前
已完结
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
1个月前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
1个月前
已完结
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
1个月前
已完结
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial
1个月前
已完结
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials
1个月前
已完结
GLP-1 receptor agonists
1个月前
已完结
Dibromocarbene addition to bicyclo[1.1.0]butanes: A facile route to substituted bicyclo[1.1.1]pentanes
2个月前
已完结
The expanding landscape of GLP-1 medicines
2个月前
已完结
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
